PSTX POSEIDA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended September 30, 2024, POSEIDA THERAPEUTICS INC reported revenue of $71.7M (up 667.2% from a year earlier), net income of $20.2M and diluted EPS of $0.21; over the last four quarters revenue was $151M and net income −$60.8M; for the fiscal year ended December 2023 revenue was $64.7M, down 50.4% on the year before.
PSTX annual revenue and earnings
- Fiscal year ended Dec 2023: revenue $64.7M, gross profit n/a, operating income −$130M, net income −$123M (margin -190.8%), EPS −$1.37
- Fiscal year ended Dec 2022: revenue $130M, gross profit n/a, operating income −$59.9M, net income −$64.0M (margin -49.0%), EPS −$0.89
- Fiscal year ended Dec 2021: revenue $31.2M, gross profit n/a, operating income −$141M, net income −$125M (margin -400.1%), EPS −$2.01
PSTX quarterly revenue and earnings
- Quarter ended Sep 30, 2024: revenue $71.7M (up 667.2% year over year), net income $20.2M, EPS $0.21
- Quarter ended Jun 30, 2024: revenue $26.0M (up 29.8% year over year), net income −$31.4M, EPS −$0.32
- Quarter ended Mar 31, 2024: revenue $28.1M (up 172.1% year over year), net income −$24.3M, EPS −$0.25
- Quarter ended Dec 31, 2023 (from the annual report): revenue $25.0M (up 148.7% year over year), net income −$25.3M, EPS −$0.25
- Quarter ended Sep 30, 2023: revenue $9.35M (down 92.0% year over year), net income −$31.8M, EPS −$0.35
- Quarter ended Jun 30, 2023: revenue $20.0M (up 641.2% year over year), net income −$27.5M, EPS −$0.32
- Quarter ended Mar 31, 2023: revenue $10.3M (up 620.8% year over year), net income −$38.8M, EPS −$0.45
- Quarter ended Dec 31, 2022 (from the annual report): revenue $10.1M, net income −$33.3M, EPS −$0.19
- Quarter ended Sep 30, 2022: revenue $116M, net income $70.4M, EPS $0.92
- Quarter ended Jun 30, 2022: revenue $2.70M, net income −$43.0M, EPS −$0.69
- Quarter ended Mar 31, 2022: revenue $1.44M, net income −$58.1M, EPS −$0.93
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $1.47M, EPS $0.03
- Quarter ended Sep 30, 2021: revenue n/a, net income −$42.4M, EPS −$0.68
- Quarter ended Jun 30, 2021: revenue n/a, net income −$45.7M, EPS −$0.74
- Quarter ended Mar 31, 2021: revenue n/a, net income −$38.3M, EPS −$0.62
PSTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2023: operating cash flow −$92.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$26.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$103M, share buybacks n/a
PSTX balance sheet
- Sep 30, 2024: cash $49.3M, total assets $294M, total liabilities $206M, shareholders' equity $87.2M, long-term debt $58.9M
- Jun 30, 2024: cash $30.5M, total assets $299M, total liabilities $238M, shareholders' equity $60.8M, long-term debt $58.8M
- Mar 31, 2024: cash $53.3M, total assets $263M, total liabilities $178M, shareholders' equity $84.6M, long-term debt $58.7M
- Dec 31, 2023: cash $44.5M, total assets $274M, total liabilities $170M, shareholders' equity $104M, long-term debt $58.6M
- Sep 30, 2023: cash $25.5M, total assets $302M, total liabilities $179M, shareholders' equity $124M, long-term debt $58.5M
- Jun 30, 2023: cash $49.9M, total assets $281M, total liabilities $146M, shareholders' equity $135M, long-term debt $58.4M
- Mar 31, 2023: cash $40.1M, total assets $314M, total liabilities $156M, shareholders' equity $158M, long-term debt $58.3M
- Dec 31, 2022: cash $81.4M, total assets $352M, total liabilities $164M, shareholders' equity $188M, long-term debt $58.3M
What is PSTX's revenue?
POSEIDA THERAPEUTICS INC reported $151M of revenue over its last four quarters, through September 30, 2024.
Is PSTX profitable?
No. POSEIDA THERAPEUTICS INC lost $60.8M over the last four quarters.
What is PSTX's EPS?
Diluted earnings per share over the last four quarters were −$0.61; $0.21 in the latest quarter.